September 14, 2018
Regeneron, a biopharmaceutical company, plans to invest approximately $800 million over seven years to expand its laboratory space, manufacturing capacity, and warehouse facilities at the company's site in Rensselaer, New York and create 1,500 new full-time jobs. Read More
Alcon, the eye-care division of Novartis, has announced plans to locate its future global headquarters in the Canton of Geneva, Switzerland, following completion of its proposed spin-off from Novartis. Novartis announced its intention to spin off Alcon into a separately traded standalone company in July. Read More
Following a business review, GlaxoSmithKline (GSK) has announced staff reductions of up to 650 employees across its US business, primarily in sales and back-office operations. These changes are part of global restructuring program announced by the company in its second-quarter results. Read More
Mylan has purchased the worldwide rights to commercialize two of Novartis’ global cystic fibrosis products consisting of TOBI Podhaler (tobramycin inhalation powder) and TOBI solution (tobramycin inhalation solution) for approximately $463 million to support its respiratory portfolio. Read More
Cambrex, a contract manufacturer of small-molecule active pharmaceutical ingredients (APIs), has completed its acquisition of Halo Pharma, a CDMO, for approximately $425 million. The addition of Halo Pharma adds formulation development and finished dosage manufacturing capabilities to Cambrex’s global API manufacturing network. Read More
Lannett, a generic-drug manufacturer, has stopped expansion plans for its active pharmaceutical ingredient (API) manufacturing plant in Cody, Wyoming due to changing market conditions for pain-management APIs. Read More
Avara Pharmaceutical Services, a CDMO, has acquired Sandoz’s sterile manufacturing facility for injectable medicines in Canada. The move follows other recent facility acquisitions by Avara to bring the number of manufacturing and development sites operated by Avara worldwide to 10.  Read More
The FDA has published a draft guidance that discusses how the risk of one or more changes to a drug-substance manufacturing process during the drug-product application postapproval period should be assessed. Read More
Thermo Fisher Scientific has agreed to acquire the advanced bioprocessing business of Becton, Dickinson and Company, a medical technology company. The business combines a technical services program with a variety of peptones designed to enhance cell-culture media formulations to improve yield and reduce variability in biopharmaceutical applications. Read More
PCI Pharma Services (PCI) has agreed to acquire Sherpa Clinical Packaging, a provider of clinical-trial supply services. The addition of Sherpa’s capabilities enables PCI to support customers from early phases of clinical development through to commercial launch. Read More
Teva Pharmaceutical Industries has appointed John Nason, Teva’s Senior Vice President of European Technical Operations, as President, Teva Active Pharmaceutical Ingredients, to lead the company’s vertically integrated business unit responsible for the development, manufacture, marketing, and sales of bulk APIs for both third-party manufacturers and Teva.  Read More
Top Industry News is published and distributed by the Drug, Chemical & Associated Technologies Association (DCAT). The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum. For more information, visit .